Pimea AI
A personalized healthcare app (mHealth) for allergies that accesses the subconscious mind to retrain the immune system to avoid, or reduce, allergy inflammation for a long period
Startup Pre-Funding Health Tech & Life Sciences Est. 2022
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
1
1-10 employees
Confidence
95/100
Patents
1
About
A steady increase in the prevalence of allergic diseases globally has occurred with about 30-40% of the world population now being affected by one or more allergic conditions. Modern healthcare bodies and authorities agree that they cannot cure an allergy, but can only treat the symptoms by either avoiding the allergen, taking medications (Antihistamines and Steroids, epinephrine (EpiPen)), or getting into a long-lasting treatment process of 2-4 years, called Immunotherapy. We are developing a digital personalized healthcare therapy that will revolutionize the global allergy industry and the a/m concept by offering a nonintrusive solution that leverages decades of impactful alternative medicine therapies and techniques to overcome allergies. Our solution utilizes advanced algorithms that analyze patients' physiological parameters to autonomously administer a proprietary therapeutic protocol that by accessing the subconscious mind retrains the immune system to avoid, or reduce, allergy inflammation for a long period, which means developing resilience to the disease and prevent allergy symptoms for an extended period. Our methodology is firmly rooted in the modern holistic healthcare paradigm, which seamlessly integrates conventional medicine with complementary and alternative practices. The treatment, a quick 20- to 30-minute session, can be seamlessly integrated into mainstream healthcare or employed as a standalone therapy. Drawing inspiration from the scientific field of psychoneuroimmunology, our treatments address each patient's mental state and mindset. Pimea AI is committed to ushering in a new era of allergy relief that prioritizes individual well-being and long-term health.
Classification
Sector
Health Tech & Life SciencesDigital HealthcareDigital TherapeuticsMedical DevicesMedical Treatment & Therapeutics
Core Technology
SensingPlatforms & InterfacesSoftwareArtificial Intelligence
Target Customer
ConsumersHealthcare & Life SciencesHealthcareProvidersPatients
Business Model
B2CB2B2CB2B
Tags
healthcare-providersalgorithmspersonalized-treatmentchronic-patientsautoimmune-diseasesimmunologydigital-therapeuticsdigital-healthcaresoftware-applicationsallergynon-invasivetreatmentsartificial-intelligencedata-analyticsneurologyclinicspharma-companiesmachine-learning
Details
Product Stage
R&D
Employees
1-10
Exact Count
3
District
Center District
Founded
2022
Locations
Tel Aviv-Yafo, Israel
Links
Website
Admin
Last Update
Mar 21, 2024
Verified by
Yotam Maman
Claimed
Yes
Missing
video or image, funding rounds, news, markets, external profiles
Team (1)
Omer Hevlin
Founder & CEO
Founder
Internal
Created by
Omer Hevlin (omer@silverline-ia.com)
Created
2021-05-30T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)